Park Jung-Wee, Lee Dong-Hoon, Park Ki-Tae, Kim Sung Hwa, Lee Young-Kyun
Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea.
Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul 03080, South Korea.
JBMR Plus. 2024 Dec 28;9(3):ziae171. doi: 10.1093/jbmrpl/ziae171. eCollection 2025 Mar.
Paget's disease of bone (PDB) is a chronic disorder characterized by abnormal bone remodeling, leading to enlarged and deformed bones, and commonly affecting older adults. The disease frequently involves the pelvis, skull, spine, and long bones. Despite significant geographical variations in PDB prevalence, data from Asian populations remain sparse. This study evaluates the incidence, skeletal distribution, comorbidities, and bisphosphonate use for PDB in South Korea from 2010 to 2020, using a retrospective analysis of the Korean Health Insurance Review and Assessment database. We identified 4252 patients diagnosed with PDB via ICD-10 codes (M880, M888, and M889) over the study period. The primary outcome measured was the incidence of PDB, stratified by sex and age, with secondary outcomes including anatomical site involvement, associated comorbidities, and bisphosphonate use. The mean age of patients was 56.3 ± 14.8 yr, with a mean prevalence of 1.20 per 100 000 and an age-adjusted incidence ranging from 0.38 to 1.26 per 100 000 person-years. The incidence of PDB decreased in men but showed a significant increase in women, especially after 2015. The spine (23.5%) and pelvis & femur (17.0%) were the most commonly affected sites. Gastritis and gastroesophageal reflux disease (91.6%), upper respiratory infections (78.9%), and endocrine disorders (69.5%) were frequent comorbidities. Despite the established efficacy of bisphosphonates in managing PDB, only 9.8% of patients received these treatments, predominantly etidronate (3.2%) and alendronate (2.2%). This study is the first comprehensive epidemiologic assessment of PDB in South Korea, highlighting a low but increasing incidence, particularly among women. The findings underscore the need for greater clinical awareness and more proactive management strategies, especially regarding the use of bisphosphonates to improve patient outcomes.
骨佩吉特病(PDB)是一种慢性疾病,其特征为异常的骨重塑,导致骨骼增大和变形,常见于老年人。该病常累及骨盆、颅骨、脊柱和长骨。尽管PDB的患病率在地理上存在显著差异,但来自亚洲人群的数据仍然稀少。本研究利用韩国健康保险审查与评估数据库进行回顾性分析,评估了2010年至2020年韩国PDB的发病率、骨骼分布、合并症以及双膦酸盐的使用情况。我们通过ICD - 10编码(M880、M888和M889)在研究期间确定了4252例诊断为PDB的患者。测量的主要结局是按性别和年龄分层的PDB发病率,次要结局包括解剖部位受累情况、相关合并症以及双膦酸盐的使用情况。患者的平均年龄为56.3±14.8岁,平均患病率为每10万人1.20例,年龄调整发病率为每10万人年0.38至1.26例。PDB的发病率在男性中有所下降,但在女性中显著上升,尤其是在2015年之后。脊柱(23.5%)和骨盆及股骨(17.0%)是最常受累的部位。胃炎和胃食管反流病(91.6%)、上呼吸道感染(78.9%)以及内分泌疾病(69.5%)是常见的合并症。尽管双膦酸盐在治疗PDB方面已证实有效,但只有9.8%的患者接受了这些治疗,主要是依替膦酸(3.2%)和阿仑膦酸(2.2%)。本研究是韩国对PDB的首次全面流行病学评估,突出了发病率虽低但呈上升趋势,尤其是在女性中。研究结果强调需要提高临床认识并采取更积极的管理策略,特别是在使用双膦酸盐以改善患者预后方面。